AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23808787 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) intervention for 12 months
Number of subjects: 136
Study 23808787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 136
Study 23808787 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) intervention
Number of subjects: 136
Study 22441222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal high-voltage electrical stimulation (HVES)
Number of subjects: 20
Study 22441222 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham treatment with disconnected HVES equipment)
Number of subjects: 20
Study 22441222 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups after treatment
Number of subjects: 20
Study 18420939 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily in addition to disease-modifying anti-rheumatic drugs
Number of subjects: 150
Study 18420939 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (control group)
Number of subjects: 150
Study 18420939 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in remission at 2 years
Number of subjects: 150
Study 18420939 — intervention group
Group type: COMPARATOR
Intervention: Patients with active disease
Number of subjects: 150
Study 17585662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential acupuncture method
Number of subjects: 144
Study 17585662 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 144
Study 16304265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) and optimal medical therapy
Number of subjects: 16
Study 16304265 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy only
Number of subjects: 16
Study 12795180 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 32
Study 12795180 — intervention group
Group type: COMPARATOR
Intervention: Clinical pathway
Number of subjects: 32
Study 10643168 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization activities in WIC including screening for vaccination status, referral to on-site WIC nurse, on-site clinic, or off-site community provider, and issuing food vouchers (3-month supply for up-to-date children, 1-month supply for not up-to-date children).
Number of subjects: 0
Study 10643168 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization activities in WIC.
Number of subjects: 0
Study 10643168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study 10643168 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral interventions (off-site and on-site).
Number of subjects: 0
Study 9031992 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg daily for 27 nights (preceded by 2 nights of placebo and followed by 3 nights of placebo)
Number of subjects: 0
Study 9031992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 nights before and 3 nights after zolpidem administration)
Number of subjects: 0
Study 1523530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (lyophilized, producing H2O2)
Number of subjects: 60
Study 1523530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1523530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 60
Study 1523530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus suppository
Number of subjects: 60
Study 6340415 — intervention group
Group type: EXPERIMENTAL
Intervention: Becotide (beclomethasone diproprionate) inhalations
Number of subjects: 26
Study 6340415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6340415 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (Becotide and placebo)
Number of subjects: 26
Study 3782678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 gm)
Number of subjects: 16
Study 3782678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31645180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (two 30- to 45-minute sessions weekly for 12 weeks)
Number of subjects: 90
Study 31645180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy
Number of subjects: 90
Study 31645180 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatments and routine daily care (Control)
Number of subjects: 90
Study 30012547 — intervention group
Group type: EXPERIMENTAL
Intervention: eMotion intervention (Web-based program combining behavioral activation and physical activity promotion)
Number of subjects: 62
Study 30012547 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 62
Study 30012547 — intervention group
Group type: EXPERIMENTAL
Intervention: eMotion intervention
Number of subjects: 62
Study 26678518 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose media buy (3 times standard dose)
Number of subjects: 8576
Study 26678518 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose media buy
Number of subjects: 8576
Study 26171398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant diet 10.000 ORAC + alpha‐lipoic acid
Number of subjects: 71
Study 26171398 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant diet 10.000 ORAC + placebo
Number of subjects: 71
Study 26171398 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71
Study 23920107 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific education program on appropriate indications of intravenous lines
Number of subjects: 1910
Study 23920107 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 1910
Study 21914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified two layer closure (Group C)
Number of subjects: 90
Study 21914406 — intervention group
Group type: COMPARATOR
Intervention: One layer closure (Group A)
Number of subjects: 90
Study 21914406 — intervention group
Group type: COMPARATOR
Intervention: Two layer closure (Group B)
Number of subjects: 90
Study 18693456 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus rosiglitazone (4 mg/d)
Number of subjects: 60
Study 18693456 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus metformin
Number of subjects: 60
Study 16380197 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol of verbal‐only advice on positioning and attachment, delivered at the first postnatal ward feed
Number of subjects: 370
Study 16380197 — intervention group
Group type: COMPARATOR
Intervention: Routine care by a qualified midwife
Number of subjects: 370
Study 16380197 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 370
Study 16380197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study 14617267 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct heel loading
Number of subjects: 27
Study 14617267 — intervention group
Group type: COMPARATOR
Intervention: Ankle-cuff compression
Number of subjects: 27
Study 10911006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (infused at a rate of 0.015 microg/kg/min)
Number of subjects: 432
Study 10911006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (infused at a rate of 0.030 microg/kg/min)
Number of subjects: 432
Study 10911006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 10911006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (up to 7 days)
Number of subjects: 432
Study 10911006 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous therapy
Number of subjects: 432
Study 8769617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily)
Number of subjects: 143
Study 8769617 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (4 X 10(6) U)
Number of subjects: 143
Study 1330127 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group therapy
Number of subjects: 135
Study 1330127 — intervention group
Group type: COMPARATOR
Intervention: Brief counselling
Number of subjects: 135
Study 1330127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 135
Study 4073101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (3 g) plus clavulanate potassium (200 mg) administered intravenously
Number of subjects: 78
Study 4073101 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (125 to 200 mg/kg per day) administered intravenously
Number of subjects: 78
Study 4073101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 4073101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanate potassium
Number of subjects: 78
Study 4073101 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 78
Study 31024557 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-ICLC (1.4 mg subcutaneously, two consecutive daily doses)
Number of subjects: 15
Study 31024557 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Number of subjects: 15
Study 31024557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27681227 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare intervention (SCOPE)
Number of subjects: 124
Study 26870827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence priming (compensation model)
Number of subjects: 57
Study 26870827 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource priming (capitalization model)
Number of subjects: 57
Study 26870827 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive resource priming (capitalization model)
Number of subjects: 57
Study 24933728 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST)
Number of subjects: 10
Study 24933728 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-EMST (after 3 months of detraining)
Number of subjects: 10
Study 24933728 — intervention group
Group type: COMPARATOR
Intervention: Post-EMST to post-detraining period
Number of subjects: 10
Study 22260209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse 1
Number of subjects: 67
Study 22260209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse 2
Number of subjects: 67
Study 19963228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively enhanced program
Number of subjects: 0
Study 19963228 — intervention group
Group type: COMPARATOR
Intervention: Traditional home visitation program
Number of subjects: 0
Study 18197495 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human growth hormone (rhGH) 0.15 IU/kg daily for 7 days postoperatively
Number of subjects: 48
Study 18197495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (menstruum) injection daily for 7 days postoperatively
Number of subjects: 48
Study 15990570 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg daily dose of hydroxyurea
Number of subjects: 115
Study 15990570 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of hydroxyurea (900 mg and 1200 mg)
Number of subjects: 115
Study 12187500 — intervention group
Group type: EXPERIMENTAL
Intervention: Product R
Number of subjects: 43
Study 12187500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10541778 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/day)
Number of subjects: 16
Study 10541778 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (10 mg on day 1 and 2.5‐10 mg on days 2‐21)
Number of subjects: 16
Study 7529484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 216
Study 7529484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 12283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 45
Study 12283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipropyline
Number of subjects: 45
Study 12283629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 343489 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (5‐‐10 mg per kg body weight)
Number of subjects: 42
Study 343489 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 42
Study 343489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30782183 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antimicrobial prophylaxis (AP) with cotrimoxazole
Number of subjects: 1574
Study 30782183 — intervention group
Group type: COMPARATOR
Intervention: 3-day antimicrobial prophylaxis (AP) with cotrimoxazole
Number of subjects: 1574
Study 30067429 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior composite restorations with glass ionomer cement providing pulp protection
Number of subjects: 194
Study 26995364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABC)
Number of subjects: 176
Study 26995364 — intervention group
Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 176
Study 24257591 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily monitoring of traumatic symptoms and substance use behaviors using PDAs
Number of subjects: 202
Study 24257591 — intervention group
Group type: COMPARATOR
Intervention: No daily monitoring assessments (only pre- and post-monitoring online assessments)
Number of subjects: 202
Study 22088145 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbicide clinical trial participation (women)
Number of subjects: 157
Study 22088145 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbicide clinical trial participation (men)
Number of subjects: 157
Study 19041143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diathermy tonsillectomy (BDT)
Number of subjects: 150
Study 19041143 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy (CDT)
Number of subjects: 150
Study 17572380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load condition
Number of subjects: 3
Study 17572380 — intervention group
Group type: COMPARATOR
Intervention: No cognitive load condition
Number of subjects: 3
Study 15451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (n=857)
Number of subjects: 1702
Study 15451221 — intervention group
Group type: COMPARATOR
Intervention: Parenteral penicillin (n=845)
Number of subjects: 1702
Study 11394606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial eminence fracture treatment
Number of subjects: 3
Study 11394606 — intervention group
Group type: COMPARATOR
Intervention: Anterior cruciate ligament deficiency
Number of subjects: 3
Study 11394606 — intervention group
Group type: COMPARATOR
Intervention: Anterior cruciate ligament reconstruction using bone‐patellar tendon‐bone autografts
Number of subjects: 3
Study 9596326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 45
Study 9596326 — intervention group
Group type: COMPARATOR
Intervention: Traditional diathermic device
Number of subjects: 45
Study 8092118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: surgery if possible, otherwise biopsy followed by whole-brain irradiation to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.), and BCNU (80 mg/m2 i.v.) every 6 weeks
Number of subjects: 108
Study 8092118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: irradiation as Group I plus VP16 (75 mg/m2) every 3 weeks and BCNU (50 mg/m2 i.v.) every 6 weeks
Number of subjects: 108
Study 8092118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: 60 Gy in 30 fractions to the tumor bed plus VCR (2 mg i.v.), BCNU (50 mg/m2 i.v.), and CDDP (15 mg/m2 i.v.) every 6 weeks
Number of subjects: 108
Study 2979243 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (1.91 mg)
Number of subjects: 10
Study 2979243 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine cigarettes (0.17 mg)
Number of subjects: 10
Study 28681570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost (Lumigan 0.01%), applied bid to the proximal nail fold
Number of subjects: 45
Study 28681570 — intervention group
Group type: COMPARATOR
Intervention: Vehicle drops (control group)
Number of subjects: 45
Study 27006512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 8494
Study 27006512 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 8494
Study 25073015 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine only
Number of subjects: 0
Study 25073015 — intervention group
Group type: COMPARATOR
Intervention: UMTS MP only
Number of subjects: 0
Study 25073015 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and MP
Number of subjects: 0
Study 25073015 — intervention group
Group type: COMPARATOR
Intervention: No caffeine and no MP
Number of subjects: 0
Study 22545738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 259
Study 22545738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBASP and nefazodone
Number of subjects: 259
Study 22545738 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 259
Study 19447020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day)
Number of subjects: 40
Study 19447020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day) plus green tea extract (200 mg/day)
Number of subjects: 40
Study 19447020 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 40
Study 17218777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1E10 anti-idiotype vaccine (2 mg of aluminum hydroxide-precipitated 1E10 MAb, four biweekly injections followed by six doses at 28-day intervals)
Number of subjects: 9
Study 17218777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1E10 anti-idiotype vaccine
Number of subjects: 9
Study 16086128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks Screening Test (SSST)
Number of subjects: 29
Study 16086128 — intervention group
Group type: COMPARATOR
Intervention: Control group (homogeneous subjects)
Number of subjects: 29
Study 12196750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (EE/LNG)
Number of subjects: 371
Study 12196750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 8722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 8722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0
Study 8722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 8722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate medical and surgical therapy
Number of subjects: 0
Study 2158759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalized bupivacaine (0.25% with 8.4% sodium bicarbonate)
Number of subjects: 120
Study 2158759 — intervention group
Group type: COMPARATOR
Intervention: Unaltered bupivacaine (0.25% with normal saline)
Number of subjects: 120
Study 448786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (15 mg/kg single oral dose)
Number of subjects: 0
Study 448786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (15 mg b.d. for a single day)
Number of subjects: 0
Study 31176255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 15
Study 31176255 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 15
Study 31176255 — intervention group
Group type: COMPARATOR
Intervention: Without stretching (WS)
Number of subjects: 15
Study 28219295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical schemas (beliefs about medicines)
Number of subjects: 0
Study 28219295 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct recall of side effects
Number of subjects: 0
Study 26936842 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (Cabernet Sauvignon variety)
Number of subjects: 10
Study 26936842 — intervention group
Group type: COMPARATOR
Intervention: Ethanol solution
Number of subjects: 10
Study 26936842 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (Robola variety)
Number of subjects: 10
Study 26936842 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 22954403 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin and rifampicin combination
Number of subjects: 43
Study 22954403 — intervention group
Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 43
Study 21360202 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (water with carbohydrates)
Number of subjects: 14
Study 21360202 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study 19944006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy (SLIT) for children with allergic rhino-conjunctivitis and seasonal asthma for a duration of no less than three years.
Number of subjects: 0
Study 19944006 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) for pediatric allergic rhinitis and asthma.
Number of subjects: 0
Study 19944006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 17762711 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg)
Number of subjects: 12
Study 17762711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14752635 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg oral ALA (low-dose)
Number of subjects: 25
Study 14752635 — intervention group
Group type: COMPARATOR
Intervention: 60 mg/kg oral ALA (high-dose)
Number of subjects: 25
Study 14752635 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg in two fractions 4 and 6 h before PDT
Number of subjects: 25
Study 11162974 — intervention group
Group type: EXPERIMENTAL
Intervention: AGN 192024
Number of subjects: 25
Study 10359882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 6
Study 10359882 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg/1.73 m2)
Number of subjects: 6
Study 7662379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioflo valve
Number of subjects: 170